New drug KP-001 tested for interactions with common meds
NCT ID NCT06821698
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This completed Phase 1 study looked at how a new drug called KP-001 interacts with other medications in 38 healthy adults. The study measured how KP-001 affects the body's processing of rosuvastatin (a cholesterol drug) and caffeine, and how fluvoxamine (an antidepressant) affects KP-001 levels. The goal was to understand potential drug interactions, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KP-001
What this could lead to
If successful, this study could help determine safe dosing for KP-001 when taken with other common drugs.
What could go wrong
This is a very early, small study in healthy volunteers, not patients. It only looks at drug levels in the blood, not whether KP-001 works for any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Parexel International Early Phase Clinical Unit
Glendale, California, 91206, United States